The role of complement protein and complement regulatory protein in diabetic nephropathy

Diabetic nephropathy is one of the main causes of end-stage renal disease, with dysregulation of the complement system playing a critical role in its pathogenesis. However, the specific mechanisms, key effector molecules, and relevant therapeutic targets still require further investigation.

This review involves searching databases such as PubMed and Web of Science to identify and integrate key studies on the role of complement proteins and regulatory proteins in diabetic nephropathy. This is a narrative review integrating experimental and clinical studies, rather than a formal systematic review. The analysis systematically examines the mechanisms of the complement system in disease progression and its potential as a therapeutic target.

This review collectively suggests that the hyperglycemic environment characteristic of diabetic nephropathy activates both the complement alternative and lectin pathways, continuously driving the complement cascade and generating key effector molecules (such as C5a and the membrane attack complex). These molecules directly lead to podocyte injury, glomerular inflammation, and fibrosis. Concurrently, dysfunction of complement regulatory proteins (such as CD59 and CD55) results in excessive activation of complement proteins, collectively accelerating the progression of diabetic nephropathy to end-stage renal disease. In terms of intervention strategies, inhibitors targeting specific complement components (such as C3 and C5) have shown protective effects in preclinical models.

Dysregulation of the complement system is an important pathogenic mechanism in diabetic nephropathy. A deeper understanding of this regulatory network provides a solid theoretical foundation for developing targeted and precise therapeutic strategies aimed at the complement system.